ARAX Holdings files 2024 Form 10-K after BF Borgers audit crisis
ARAX Holdings successfully filed its 2024 Form 10-K on June 10, 2026, completing restated 2023 filings after being impacted by the BF Borgers audit fraud that affected over 1,500 S…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
ARAX Holdings successfully filed its 2024 Form 10-K on June 10, 2026, completing restated 2023 filings after being impacted by the BF Borgers audit fraud that affected over 1,500 S…
The FDA granted an Emergency Use Authorization for generic Nitenpyram Tablets to treat New World screwworm infestations in dogs and cats weighing at least two pounds and at least f…
The company updated its Second Amended and Restated Bylaws, modifying provisions for stockholder meetings, board governance, and special meeting procedures. The amendment clarifies…
Theriva Biologics published Phase 1 clinical trial results demonstrating that VCN-01 oncolytic adenovirus combined with durvalumab produced prolonged overall survival in heavily pr…
Enliven Therapeutics announced updated positive Phase 1 data for ELVN-001 in chronic myeloid leukemia with 61% overall response rates and FDA alignment on the 80 mg dose for the pi…
InspireMD announced positive 30-day results from CGUARDIANS II trial showing 100% acute device success with zero major adverse events for its CGuard Prime 80cm stent in TCAR proced…
Prairie Operating Co. executed a second amendment to its credit agreement effective April 1, 2026, redetermining and reaffirming its borrowing base at $475 million with Citibank as…
Rafael Holdings completed enrollment in its pivotal Phase 3 TransportNPC trial for Niemann-Pick disease Type C and expects to submit an NDA in the second half of 2026 following a p…
Silence Therapeutics presented Phase 1 follow-up data showing divesiran reduced phlebotomy requirements from 80 procedures to 5 during treatment, with benefits persisting post-dose…
Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated with bexobrutideg, with durable r…
Shoe Station Group, Inc. (Shoe Carnival's subsidiary) filed amended and restated articles of incorporation with the Indiana Secretary of State, updating its corporate governance st…
Tilly's Inc. filed the Fourth Amended and Restated 2012 Equity and Incentive Award Plan to provide flexibility in compensating board members, employees, and consultants. The plan u…
Factorial Energy Inc. established its corporate structure with authorization for 750 million shares across common and preferred stock classes. The filing represents routine incorpo…
BIO-key International received a notice from Nasdaq stating the company failed to timely file its Form 10-Q for the quarter ended March 31, 2026, violating Listing Rule 5250(c)(1).…
Tectonic Therapeutic completed enrollment in its APEX Phase 2 clinical trial testing TX45 in pulmonary hypertension patients, with 72% of participants in the targeted severe diseas…
Iovance Biotherapeutics announced that Australia's TGA approved Amtagvi (lifileucel) for previously treated advanced melanoma, marking the company's third marketing authorization f…
American Eagle Outfitters and lenders executed Amendment No. 2 to extend the maturity date of its secured credit agreement to June 2031. The extension provides operational flexibil…
Sadot Group Inc. submitted an amended certificate of incorporation in an 8-K filing. The filing provides updated corporate governance documentation for the company.
AIM ImmunoTech Inc. amended its bylaws effective June 9, 2026, modifying Section 1.9 of Article I to clarify voting procedures, proxy rules, and the voting standard for director el…
Perceptive Capital Solutions Corp proposed amendments to extend its business combination deadline from the original timeframe to June 13, 2027, with provisions for trust account re…